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Abstract 
Syndecan-1 is a trans-membrane heparan sulfate proteoglycan that localizes in 
epithelial cells and has been shown to be present in normal hepatocytes. It is 
thought to be involved in processes such as cell growth, differentiation and 
adhesion. However, the  clinical data regarding syndecan-1 in patients with 
hepatocellular carcinoma (HCC) are scarce and controversial. Therefore, we 
need to evaluate the effects of HCC on the serum levels of syndecan-1. Thus, 
40 patients with HCC and 31 patients with liver cirrhosis were physically 
examined. Blood samples were taken for measurements of routine markers 
(sGPT, sGOT, bilirubin, albumin, and α-fetoprotein), as well as serum levels of 
interleukin (IL)-6 and syndecan-1. Patients with liver cirrhosis showed significant 
increase in serum IL-6 as compared with HCC patients and the control subjects. 
Serum level of syndecan-1 was significantly increased in HCC patients as 
compared with the cirrhotic and control groups. In addition, significant positive 
correlations between  syndecan-1 and serum levels of ALT, AST in HCC 
patients were found. Moreover, syndecan-1 increased significantly with 
increasing stage of Barcelona-Clinic Liver Cancer Group diagnostic and 
treatment strategy. In conclusion, the development of HCC is accompanied by a 
significant elevation in serum syndecan-1 levels. The increase in serum 
syndecan-1 may be linked with progression of HCC. 
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Introduction 
Hepatocellular carcinoma (HCC) has become  the third most common malignancy 
worldwide with very poor prognosis, rendering it the fourth highest cause of cancer-related 
deaths. In Africa, liver cancer has been ranked as the fourth common cancer, and most of 
liver cancers are HCC [1]. In addition, Egypt has the highest prevalence of HCV worldwide 
and has rising rates of HCC. HCC comprises nearly 6% of all incident cancer cases 
worldwide. Moreover, HCC is the second most frequent cause of cancer incidence and 
mortality among men in Egypt. Hospital-based studies from Egypt have reported an 
increase in the relative frequency of all liver-related cancers in Egypt (>95% as HCC), from 
4.0% in 1993 to 7.3% in 2003 [2]. 
It is very important to detect HCC and the recurrence at its earlier period. By reasons of 
convenience, inexpensiveness, and the satisfactory accuracy, serum tumor markers have 
been used as an effective method for detecting malignant tumors for a long time, and they 
could be valuable supplementary to ultrasonography and computer tomography in the 
diagnosis of HCC. Using the appropriate single or combination of tumor markers may 
improve the effectiveness in screening HCC patients [3]. Currently, standard surveillance 
includes  a  combination  of  6  monthly  ultrasound  scans  (USS)  and  serum  α-fetoprotein 
measurements, but this strategy dose not reliably detect the disease in its early stages [4]. 
Therefore, it is very clear that there is an imperious need for newer markers with greater 
accuracy in diagnosis of early HCC. 
Interleukin (IL)-6 is a glycoprotein of 21–28 kDa molecular weight and consists of 184 
amino acids [5]. IL-6 is a pleiotropic cytokine that plays a central role in hematopoiesis, as 
well as in the differentiation and growth of a number of cells of different histologic origin, 
e.g. endothelial cells, keratinocytes, neuronal cells, osteoclasts, and osteoblasts. 
Moreover, IL-6 induces the hepatic acute phase response by modulating the transcription 
of several liver-specific genes during inflammation [6]. 
Syndecan-1, a trans-membrane heparan sulfate proteoglycan, localizes in epithelial cells 
and has been shown to be present in normal hepatocytes. It interacts with growth factors, 
matrix components and other extracellular proteins and is thought to be involved in 
processes such as cell growth, differentiation and adhesion [7]. Syndecan-1 plays roles in 
early development and wound healing [8]. The expression of syndecan-1 appears 
generally down-regulated in human carcinomas and in experimental cancer models, 
whereas transfectional expression of syndecan-1 in cultured cancer cells has been shown 
to inhibit their growth and other aspects of malignant behavior [7]. 
Altered levels of the pro-inflammatory cytokines, IL-6, have been associated with morbidity 
and disease activity in an astonishing variety of cancers. In light of these observations, we 
tried to explore the prognostic role of IL-6 in patients with HCC that might be correlated 
with clinical efficacy by comparing clinical outcome. In addition, the role of syndecan-1 in 
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Sci Pharm. 2012; 80: 179–188 
previously reported [9]. Therefore, the prognostic role syndecan-1 in patients with HCC will 
be also evaluated. 
Experimental 
Patients 
From August to December 2010, 40 patients with HCC (9 ♀ and 31 ♂; aged 45–80 years 
with a mean±SE of 57.6±1.39) were selected from the Oncology Unit, Mansoura 
University, Mansoura, Egypt. Since all HCC patients in this study have cirrhosis as 
underlying liver disorder and in order to nullify the effect of cirrhosis on the level of studied 
parameters, a group of 31 cirrhotic patients (5 ♀ and 26 ♂; aged 38–59 years with a 
mean±SE of 53.7±1.76) without any evidence of HCC was used and selected from the in-
patient Clinics of Specialized Medical Hospital, Mansoura University, Mansoura, Egypt. 
The study was approved by the local institutional ethical committee and patients’ consents 
were obtained according to the regulations of the Egyptian Ministry of Health. All cases 
involved in this study were clinically, radiologically and pathologically examined in the 
Oncology Unit and the Specialized Medical Hospital, Mansoura University. HCC was 
diagnosed by abdominal ultrasonography and serum AFP, with or without triphasic 
computed tomography scan and/or liver histopathology. Severity of liver disease was 
assessed by Child-Pugh classification [10]. The stage and management were defined 
according to the Barcelona-Clinic Liver Cancer Group diagnostic and treatment strategy 
(BCLC) [11]. 
Patients with other types of malignancy, advanced organ failure, active infection and 
advanced medical co-morbidity were excluded from the study. 
Control group 
The control group consisted of 15 healthy individuals (4 ♀ and 11 ♂; aged 30-64 years 
with a mean±SE of 50.7±2.7) with no apparent evidence of active disease or medical 
disorders. 
Blood sampling 
5 ml of fasting blood was collected by vein puncture from each patient and control subject 
and subsequently divided into two portions. The first portion (1 ml) was collected in tubes 
containing ethylene diamine tetra acetic acid (EDTA) and was used for blood picture 
investigation within 5 h. The second portion (4 ml) was left to clot for 20–30 min at room 
temperature and followed by centrifugation at 1500 r.p.m for 10 min. The serum was then 
transferred to a polypropylene tube and if the analysis was not performed immediately, the 
samples were frozen and maintained at −80°C until use. 
Analysis of biochemical parameters 
Serum  ALT,  AST,  alkaline  phosphatase,  γ-Glutamyl transferase activities as well as 
albumin and total bilirubin concentrations were measured using standard methodologies. 
Hemoglobin concentration was determined by a colorimetric method. Red blood 
corpuscles, white blood cells and platelets were counted by hemocytometer apparatus. 182  H. A. Metwaly et al.:   
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Serum α-fetoprotein, Interleukin-6 and syndecan-1 concentrations were measured using 
commercially available ELIZA kits from (Ameritek USA company, Orgenium Laboratories 
Business Unit and Cell Science Company, respectively). 
Statistical analysis 
For descriptive statistics the frequency and percentage were calculated for qualitative 
variables, the mean values ± standard deviation (SD), standard error (SE), and range were 
used for quantitative variables. For comparison between two groups student t-test was 
used. For correlation, GraphPad Instat version 3.06 was used. Statistical computations 
were done using Excel 2007 and statistical significance was predefined as P ≤ 0.05. 
Results and Discussion 
In the present study, we measured serum IL-6 and syndecan-1 levels in patients with HCC 
and healthy controls and evaluated a possible prognostic value of these markers. In most 
solid malignancies, tumor stage at presentation determines prognosis and plan of 
management. However, most patients with HCC have two diseases, liver cirrhosis and 
HCC, and complex interactions between the two have major implications for prognosis and 
treatment choice. Our study included 40 patients with HCC, and all of them are cirrhotics. 
Therefore, 31 patients with liver cirrhosis were included in the study. All the patients were 
subjected to clinical evaluation and history taking as well as measurements of serum 
levels of liver function. Patients’ characteristics were summarized in table 1. The liver 
functions of patients were summarized in table 2. 
Tab. 1.   Patients characteristics 
  HCC (n=40)  Cirrhosis (n=31) 
Sex  Male  31 (77.5%)  26 (83.9%) 
Female  9 (22.5%)  5 (16.1%) 
Diabetes  No  27 (67.5%)  21 (67.7%) 
Yes  13 (32.5%)  10 (32.3%) 
Hypertension  No  29 (72.5%)  22 (71%) 
Yes  11 (27.5%)  9 (29%) 
Ascitis  No  18 (45%)  15 (48.4%) 
Yes  22 (55%)  16 (52.8%) 
Etiology of Liver 
Disease 
HCV  25 (62.5%)  23 (74.2%) 
HBV  8 (20%)  2 (6.5%) 
Both HCV & HBV(+)  4 (10%)  2 (6.5%) 
Other  3 (7.5%)  4 (12.9%) 
Child 
A  14 (35%)  11 (35.4%) 
B  20 (50%)  14 (45.2%) 
C  6 (15%)  6 (19.4%) 
BCLC 
A  12 (30%) 
–  B  14 (35%) 
C  8 (20%) 
D  6 (15%) 
n number of patients; BCLC…Barcelona-Clinic Liver Cancer Group diagnostic and 
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Tab. 2.   Liver function tests of patients with cirrhosis and HCC as compared with the 
control subjects (mean±SE). 
  Control group  
(n=15) 
Cirrhotic group  
(n=31) 
HCC group 
(n=40) 
ALT (U/ml)  8.57±0.65  34.93±3.12*  67.47±4.51*
# 
AST (U/ml)  13.79±1.26  62.95±5.45*  78.13±3.99*
# 
Total bilirubin (mg/dl)  0.69±0.01  3.31±0.34*  1.26±0.09*
# 
Albumin (g/dl)  4.33±0.15  2.92±0.13*  3.09±0.1* 
ALP (U/l)  67.55±3.56  82.99±4.99*  120.79±7.87*
# 
γGT (U/l)  20.53±1.88  48.37±4.6*  99.54±9.96*
# 
n number of patients; * significant difference as compared with the control group at p<0.05; 
# significant difference as compared with the cirrhotic group at p<0.05. 
 
We found a significant increase in serum concentration of α-fetoprotein in HCC patients as 
compared to patients with liver cirrhosis and the control group. Similar results were 
obtained by many studies [12–15]. Some reports have indicated that α-fetoprotein has 
limited utility of differentiating HCC from benign hepatic disorders for its high false-positive 
and false-negative rates, and patients with acute exacerbation of viral hepatitis but no 
HCC may also have markedly increased α-fetoprotein levels [3]. 
IL-6 is a multifunctional cytokine with both differentiation and growth-promoting effects for 
target cells. IL-6 regulates the synthesis of a broad spectrum of acute-phase proteins in 
the liver. Up-regulated expression of the IL-6 gene appears to be involved in pathological 
conditions, and it has also been hypothesized that activation of IL-6 gene might trigger 
initial events leading to oncogenic transformation [16]. IL-6 was postulated to correlate with 
the stage of liver cirrhosis [6, 17]. Therefore, we aimed to measure the serum 
concentration IL-6 in patients with liver cirrhosis and HCC to evaluate its activity as tumor 
marker for liver malignancies. 
Tab. 3.   Serum concentration of α-fetoprotein, IL-6 and syndecan-1 in cirrhotic and HCC 
patients as compared with the control group (mean±SE). 
  Control group  
(n=15) 
Cirrhotic group  
(n=31) 
HCC group 
(n=40) 
α-fetoprotein (ng/ml)  16.06±1.59  118.5±9.65*  450.51±40.93*
# 
IL-6 (pg/ml)  69.75±0.83  132.46±11.44*  86.97±6.17*
# 
Syndecan-1 (ng/ml)  31.52±15.3  83.23±10.13*  128.64±16.45*
# 
n number of patients; * significant difference as compared with the control group at p<0.05; 
# significant difference as compared with the cirrhotic group at p<0.05. 
 
As shown in table 3, we found a significant increase in serum IL-6 in HCC patients as 
compared with control subjects similar to the results of Ataseven [18]. Furthermore, we 
found a significant decrease in serum IL-6 concentration in HCC patients as compared to 
patients with liver cirrhosis. This result coincided with those recorded by Lee [16]. 
However, Soresi [17] and Porta [6] found that there was a significant increase in serum 
IL-6 concentration of HCC patients as compared to cirrhotic patients. However, we found 184  H. A. Metwaly et al.:   
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that HCC patients showed increased serum IL-6 concentration with increased BCLC score 
(Tables 4, 6). Moreover, serum IL-6 level was positively correlated with serum 
α-fetoprotein (Table 5). In agreement, Soresi [17] suggested that HCC cells, especially in 
advanced stages of the disease, may produce and secrete IL-6 and its receptor to 
stimulate their growth by an autocrine/paracrine mechanism. It has been previously shown 
that serum IL-6 was increased in patients with liver diseases like fatty liver even before any 
increase in serum level of liver enzymes [19]. 
Tab. 4. Serum concentration of IL-6 and syndecan-1 in HCC patients in relation to BCLC 
staging (mean±SE). 
  A (n=12)  B (n=14)  C & D (n=14) 
IL-6 (pg/ml)  75.39±2.05  82.18±3.08*  96.06±5.37
# 
Syndecan-1 (ng/ml)  39.4±3.58  113.24±7.57*  264.69±37.37
# 
n number of patients; * significant difference as compared with BCLC A group at 
p<0.05; 
# significant difference as compared with BCLC B group at p<0.05. 
 
Syndecan-1 is the main heparan sulphate present on the  surface of plasma cells. 
Syndecan-1 binds to extracellular matrix proteins and to growth factors that have a 
HS-binding domain. Syndecan-1 mediates hepatocyte growth factor (HGF) binding and 
promotes its signaling [20]. Via its heparan sulphate chains, Syndecan-1 binds to a variety 
of growth and angiogenic factors and acts as a classical co-receptor for growth factor 
receptors, thus promoting cell proliferation. Moreover, Syndecan-1 interacts with ligands in 
the extracellular matrix and on cell surfaces, functioning as a cell adhesion molecule. It 
has been previously shown that Syndecan-1 is a modulator of proteolytic activities and 
chemokine functions in vivo, which regulates leucocyte recruitment and tissue remodeling 
during inflammation and wound repair [21]. 
Syndecan-1 plays an important role in the growth, survival, vasculogenesis, and 
metastasis of various cancers, including myelomas and breast, bladder, ovary, prostate 
and colon cancers. Syndecan-1 mRNA levels are up-regulated in pancreatic cancer in 
association with accelerated tumor growth [22]. As a result, we conducted the following 
research to measure the effect of liver cirrhosis or HCC on the serum level of syndecan-1. 
Tab. 5.   Correlation between serum syndecan-1 and IL-6 with the measured parameters 
in cirrhotic and HCC patients. 
Parameters 
Syndecan-1  IL-6 
Cirrhotic  
patients 
HCC  
patients 
Cirrhotic  
patients 
HCC  
patients 
ALT  −0.04  0.61*  −0.05  0.08 
AST  0.52*  0.55*  0.24*  0.69* 
Total bilirubin  0.39*  0.09  0.36*  −0.21 
Albumin  0.08  −0.23*  −0.41*  0.20 
Alkaline phosphatase  0.23  −0.08  0.06  −0.10 
γ-glutamyl transferase  0.07  −0.09  −0.1  −0.13 
α-fetoprotein  0.38*  0.28*  0.4*  0.4* 
IL-6  0.49*  0.04     
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We found a significant increase in serum syndecan-1 concentration in cirrhotic and HCC 
patients in comparison with liver cirrhosis patients or the control subjects (Table 3). In 
addition, significant positive correlations between syndecan-1 and serum activities of ALT 
and AST in HCC patients were found (Table 5). Moreover, syndecan-1 increased 
significantly with increasing stage of BCLC (Tables 4, 6). To our knowledge, this is the first 
study which measured serum level of syndecan-1 in patients with HCC. 
Tab. 6.   Multivariate analysis of serum concentration of α-fetoprotein, IL-6 and 
syndecan-1 in HCC patients in relation to BCLC staging. 
Variable  B  Odd’s Ratio  95% CI 
IL-6 (pg/ml)  1.8  1.05*  1.01–2.9 
Syndecan-1 (ng/ml)  1.2  1.1*  1.07–3.2 
α-fetoprotein (ng/ml)  4.1  1.7  0.2–8.3 
* significant at p<0.05. 
 
It  has been reported previously that proteolytic conversion of syndecan-1 from a 
membrane-bound into a soluble molecule marks a switch from a proliferative to an 
invasive tumor [23]. Soluble (shed) syndecan-1 can actively promote myeloma tumor 
growth, angiogenesis and metastasis. The finding that heparanase promotes syndecan-1 
synthesis and shedding suggests that these two molecules act synergistically to fuel and 
accelerate tumor progression [24]. The proteolytic cleavage of syndecan-1 is mediated by 
a variety of proteases of the matrix metalloproteinase (MMP) family [23]. MMP7 is 
frequently over expressed by fibroblast growth factor (FGF)-2 [25]. Off note, FGF-2 
concentration was elevated prior to the emergence of HCC [26]. Therefore, FGF-2/MMP7 
axis may be implicated in up-regulation of serum levels of syndecan-1 in HCC, which may 
reflect the aggressive character of HCC. However, further studies should be performed. 
Conclusions 
This study demonstrated that serum syndecan-1 levels are significantly elevated in 
patients with HCC, and this elevation correlates with advanced stage (BCLC) of the tumor. 
Therefore, we can conclude that: 
1.  Serum syndecan-1 is a promising diagnostic marker for HCC that may aid in 
screening and detection of HCC. 
2.  Serum syndecan-1 is a potential prognostic marker for HCC, linked with advanced 
stage of the disease. 
3.  These findings should be validated in further prospective and longitudinal studies 
recruiting a large number of patients. 
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